ProPhase Labs (OTC: PRPH) details director Warren Hirsch exit from board

Rhea-AI Filing Summary

ProPhase Labs, Inc. reported that Board member Warren Hirsch resigned from the Board of Directors, effective immediately on January 5, 2026. The company states that his resignation was not due to any disagreement regarding its operations, policies, or practices. The Board and management publicly thanked Mr. Hirsch for his service and contributions during his tenure.

false 0000868278 0000868278 2026-01-09 2026-01-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2026

PROPHASE LABS, INC.

(Exact name of Company as specified in its charter)

Delaware		000-21617		23-2577138
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

626 RXR Plaza, 6th Floor Uniondale, New York		11556
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (516) 989-0763

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14(d)-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12(b) of the Exchange Act:

Title of Each Class		Trading Symbol		Name of Each Exchange of Which Registered
Common Stock, par value $0.0005		PRPH		OTC Markets

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 5, 2026, Warren Hirsch notified the Company of his resignation as a member of the Board of Directors of ProPhase Labs, Inc. (the “Company”), effective immediately.

Mr. Hirsch’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

The Company thanks Mr. Hirsch for his service and contributions during his tenure on the Board.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ProPhase Labs, Inc.
By:	/s/ Ted Karkus
	Ted Karkus
	Chairman of the Board and Chief Executive Officer
Date: Friday, January 9, 2026

FAQ

What board change did ProPhase Labs (PRPH) disclose in this 8-K?

ProPhase Labs disclosed that Warren Hirsch resigned as a member of its Board of Directors, effective immediately on January 5, 2026.

Did Warren Hirsch resign from ProPhase Labs over a disagreement?

No. The company states that Mr. Hirsch’s resignation was not the result of any disagreement on matters related to operations, policies, or practices.

What SEC form did ProPhase Labs file for this director resignation?

ProPhase Labs filed a Form 8-K under Item 5.02, which covers departures of directors or certain officers and related matters.

How did ProPhase Labs characterize Warren Hirsch’s service on the board?

The company expressed appreciation, thanking Mr. Hirsch for his service and contributions during his tenure on the Board of Directors.

Who signed the ProPhase Labs 8-K reporting the director resignation?

The report was signed on behalf of ProPhase Labs by Ted Karkus, the company’s Chairman of the Board and Chief Executive Officer.

On which market is ProPhase Labs common stock traded?

ProPhase Labs’ common stock, par value $0.0005 per share, trades on the OTC Markets under the symbol PRPH.